MedTrace Logo

Self-paced High-intensity Interval Training and Moderate Intensity Continuous Training in Young Adults

NCT05532839 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-11-28

No results posted yet for this study

Summary

Study will be randomized clinical trial. Data will be collected from non probability convenient sampling technique. Total 26 participants from Pakistan Sports Board will be selected and randomly allocated in two different groups i.e. Group A and Group B. Group A will be given high intensity interval training and Group B will be on moderate intensity continuous training. Statistical package for the social sciences will be used to analyze the results by using parametric test after confirming normality of data.

Conditions

  • Psychophysiologic Reaction

Interventions

OTHER

High intensity interval training

The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.

OTHER

Moderate intensity continuous training

The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Muhammad Sanaullah, MS · Study Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-17
Primary Completion
2022-09-17
Completion
2022-09-17

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05532839 on ClinicalTrials.gov